Stock MVIR B MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Medivir AB

Equities

MVIR B

SE0020181014

Delayed Nasdaq Stockholm
Other stock markets
 06:07:15 2024-04-26 am EDT 		5-day change 1st Jan Change
3.07 SEK +0.66% Intraday chart for Medivir AB +14.98% +7.72%
Apr. 25 Medivir Gets Two US FDA Designations for MIV-711 MT
Mar. 21 Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medivir Gets Two US FDA Designations for MIV-711
MT
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
PU
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
AQ
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
AQ
BioStock: Medivir's partner makes clinical progress in veterinary project
AQ
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act
PU
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
AQ
BioStock: Medivir continues to accelerate development with fostrox
AQ
Medivir : The Nomination Committees proposal for the AGM
PU
Medivir to present at Investing in Oncology Forum on April 10
AQ
Medivir : Corporate Governance Report
PU
Medivir 2023 Annual Report published
AQ
Medivir : Notice of AGM 2024
PU
Notice of Annual General Meeting of Medivir AB (publ)
AQ
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.
CI
Medivir to present at Swiss Nordic Bio in Zürich on March 7
AQ
Medivir to present at the Life Science Day in Gothenburg on March 6
AQ
Change in Medivir's nomination committee before the 2024 AGM
AQ
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit
AQ
Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. News Medivir AB